Type 2 diabetes mellitus and obesity
24 papers1 finding
Associations
1PES1 expression
upin humans1
1 study
PES1 expression
upin humans1
Type 2 diabetes mellitus and obesity is associated with PES1 expression in humans.
“PES1 expression is significantly elevated in the livers of Type 2 diabetes mellitus (T2DM) and obese patients”
ReviewType 2 diabetes mellitus or obesityliver
Emerging role of PES1 in disease: A promising therapeutic target?
GeneAug 30, 2024
Latest
17 in 12 monthsClinical Nutrition ESPEN
Characterizing the Adverse Event Profile of Semaglutide: A Comprehensive U.S. Food and Drug Administration Adverse Event Reporting System-Based Pharmacovigilance Study
Cross-sectional study of 43,754 peopleSemaglutide
Journal of Oral Pathology & Medicine
Adverse Oral and Salivary Effects Associated With Glucagon-Like Peptide-1 Receptor Agonists: Clinical Insights
ReviewGLP-1 receptor agonists
Diabetes, Obesity & Metabolism
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist
Randomized trial in 90 peopleInterventions
Endocrinology, Diabetes & Metabolism
Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review
ReviewLiraglutide
Diabetes & Metabolism Journal
Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
ReviewSarcopenia
Frontiers in Immunology
Exercise modalities for adults with type 2 diabetes mellitus and obesity: comparative effects on visceral fat, metabolism, and inflammatory markers from a network meta-analysis
Meta-analysis of randomized trialsMind-body exercise
Current Medical Research and Opinion
From insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals
ReviewType 2 diabetes